Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients
Standard
Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. / Hantke, Bernd; Harbeck, Nadia; Schmalfeldt, Barbara; Claes, Ingeborg; Hiller, Oliver; Luther, Marc-Oliver; Welk, Anita; Kuhn, Walther; Schmitt, Manfred; Tschesche, Harald; Muehlenweg, Bernd.
in: BIOL CHEM, Jahrgang 384, Nr. 8, 08.2003, S. 1247-51.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients
AU - Hantke, Bernd
AU - Harbeck, Nadia
AU - Schmalfeldt, Barbara
AU - Claes, Ingeborg
AU - Hiller, Oliver
AU - Luther, Marc-Oliver
AU - Welk, Anita
AU - Kuhn, Walther
AU - Schmitt, Manfred
AU - Tschesche, Harald
AU - Muehlenweg, Bernd
PY - 2003/8
Y1 - 2003/8
N2 - Matrix metalloproteinases (MMPs) are involved in many physiological and pathophysiological processes, including tumor cell invasion and metastasis. For one member of this family, MMP-13 (collagenase-3), a new, highly specific ELISA with a sensitivity of 0.5 ng MMP-13/ml was established. The protein levels of MMP-13 in ascitic fluids of 30 patients with advanced ovarian cancer FIGO stage III (n = 19) and IV (n = 11) were measured with this ELISA. Using a cut-off value of 0.5 ng MMP-13/mg total protein, two patient subpopulations with short (median 16 months) and long (median 36 months) overall survival were identified. Together with other prognostic markers, determination of MMP-13 in ascitic fluid may help to identify patients at risk for early death and help to individualize adjuvant therapy.
AB - Matrix metalloproteinases (MMPs) are involved in many physiological and pathophysiological processes, including tumor cell invasion and metastasis. For one member of this family, MMP-13 (collagenase-3), a new, highly specific ELISA with a sensitivity of 0.5 ng MMP-13/ml was established. The protein levels of MMP-13 in ascitic fluids of 30 patients with advanced ovarian cancer FIGO stage III (n = 19) and IV (n = 11) were measured with this ELISA. Using a cut-off value of 0.5 ng MMP-13/mg total protein, two patient subpopulations with short (median 16 months) and long (median 36 months) overall survival were identified. Together with other prognostic markers, determination of MMP-13 in ascitic fluid may help to identify patients at risk for early death and help to individualize adjuvant therapy.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Animals
KW - Antibodies, Monoclonal
KW - Ascitic Fluid
KW - Cell Line
KW - Cell Line, Tumor
KW - Collagenases
KW - Enzyme-Linked Immunosorbent Assay
KW - Female
KW - Humans
KW - Matrix Metalloproteinase 13
KW - Mice
KW - Mice, Inbred BALB C
KW - Microscopy, Confocal
KW - Middle Aged
KW - Ovarian Neoplasms
KW - Sensitivity and Specificity
KW - Survival Rate
U2 - 10.1515/BC.2003.137
DO - 10.1515/BC.2003.137
M3 - SCORING: Journal article
C2 - 12974393
VL - 384
SP - 1247
EP - 1251
JO - BIOL CHEM
JF - BIOL CHEM
SN - 1431-6730
IS - 8
ER -